Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

This also equates Bril as as being a arylamide-- "Brilacidin (PMX-30063) is a synthetic, nonpeptidic, small-molecule mimetic of HDPs [53,54,55,56,57,58] (Figure 1). Building on “first principles” in medicinal chemistry, rational design tools—leveraging sophisticated informatics to fine-tune physicochemical properties and structure–activity relationships [59,60,61]—enabled brilacidin (an arylamide foldamer [62,63]) to overcome the shortcomings and challenges that have complicated the clinical development of natural HDPs [64]. These include proteolytic degradation, toxicity, lack of efficacy, malabsorption, and high cost to produce. In contrast to natural HDPs, as well as other HDP analogs, brilacidin was designed de novo [65,66,67] to be much smaller, more stable, more potent, more selective, and more economical to manufacture. Brilacidin has already been successfully tested in clinical trials and shown to exhibit potent antibacterial activity in Phase 2 clinical trials for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and anti-inflammatory activity, as supported in Phase 2 clinical trials for treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. As such, brilacidin has already demonstrated HDP-like therapeutic properties in the clinic".

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916214/